Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study

Abstract Background Venetoclax (VEN) and azacitidine (AZA) are used to treat patients with newly diagnosed acute myeloid leukaemia (AML) who are unfit for intensive chemotherapy and those with relapsed or refractory AML. Understanding the real-world usage patterns and outcomes after VEN-AZA therapy...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Jie-Fei Bai, Ting Wang, Jiang-Tao Li, Chun-Li Zhang, Long Qian, Ya-Zi Yang, Xiao-Ya Yun, Jing-Jing Yin, Fei Zhao, Wei-Dong Ding, Bao-Li Xing, Shang-Yong Ning, Lei Pei, Xiao-Dong Xu, Hui Liu, Ru Feng
Format:	Article
Language:	English
Published:	BMC 2025-06-01
Subjects:	Acute myeloid leukemia Hypomethylating agents Venetoclax Relapse Refractory
Online Access:	https://doi.org/10.1186/s12885-025-14167-z